Vice President

Brenna Raines, MHA

Brenna leads ADVI’s initiatives in policy and reimbursement, serving biopharmaceutical clients and projects.

Brenna brings to her role, as vice president at ADVI, 15 years of experience in US state and federal health policy, government and stakeholder relations, and global medical and economic projects. Before joining ADVI, she led policy analysis and research on value and economic considerations on rare disease pharmaceuticals derived from plasma and collaborated with patients, clinicians, and manufacturers to drive policy solutions. Earlier in her career, she worked for state government as a health policy analyst focused on acute care, and managed projects for CMS, AHRQ, and NIH contracts during her time as a health policy research associate at the American Institutes for Research.  

Brenna earned a Master of Health Administration degree from the University of Maryland School of Public Health, a Graduate Certificate in Public Health Economics from the Johns Hopkins Bloomberg School of Public Health, and a Bachelor of Science degree in Biology from Washington College.

CEO insights

Real analysis from people who’ve been there

Inflation Reduction Act Pharmaceuticals and Biotech State Policy

ADVI Instant: CMS Releases 2026 Notice of Benefit and Payment Parameters Proposed Rule

On October 4, 2024, the Centers for Medicare and Medicaid Services (CMS) released a proposed rule titled “HHS Notice of …

Brenna Raines, MHA
October 21, 2024

Pharmaceuticals and Biotech

ADVI Instant: CMS Releases Draft Part Two Guidance for the MPPP program

On February 15, the Centers for Medicare and Medicaid Services (CMS) released the Draft Part Two Guidance on the Medicare …

Brenna Raines, MHA
February 22, 2024

Inflation Reduction Act Pharmaceuticals and Biotech

ADVI Instant: CMS Releases CY 2025 MA Changes and Part D Redesign Instructions

On January 31, 2024, the Centers for Medicare & Medicaid Services (CMS) released the Advance Notice of Methodological Changes for …

Brenna Raines, MHA
February 7, 2024

Cell and Gene Pharmaceuticals and Biotech

ADVI Instant: CMS Releases Cell and Gene Therapy Access Model Details

On January 30, 2024, the CMS Innovation Center (CMMI) announced the release details of the Cell and Gene Therapy (CGT) Access Model …

Brenna Raines, MHA
February 7, 2024

Pharmaceuticals and Biotech

ADVI Instant: U.S. Department of Commerce Releases RFI on Draft March-In Rights Framework

On December 7, 2023, the Department of Commerce’s National Institute of Standards and Technology (NIST) released a request for information …

Brenna Raines, MHA
December 11, 2023

Inflation Reduction Act Pharmaceuticals and Biotech

ADVI Instant: IRA Implementation: CMS Patient-Focused Listening Session on Xarelto

On November 15, 2023, CMS held a Medicare Drug Price Negotiation Patient-Focused Listening Session for the selected drug Xarelto. Nine …

Brenna Raines, MHA
November 22, 2023

Inflation Reduction Act Pharmaceuticals and Biotech

ADVI Instant: IRA Implementation: CMS Patient-Focused Listening Session on Stelara

On November 14, 2023, CMS held a Medicare Drug Price Negotiation Patient-Focused Listening Session for the selected drug Stelara. Eleven …

Brenna Raines, MHA
November 22, 2023

Inflation Reduction Act Pharmaceuticals and Biotech

ADVI Instant: IRA Implementation: CMS Patient-Focused Listening Session on Januvia

On November 7, 2023, CMS held a Medicare Drug Price Negotiation Patient-Focused Listening Session for the selected drug Januvia. Five …

Brenna Raines, MHA
November 14, 2023

Reach out

Own your edge

We don’t just guide the market. We shape it. Map your market access moves with #ADVIIntelligence. Proven advantage. Unmatched partnership.